Romanian experience in child celiac disease diagnosis.

"Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Roumanian archives of microbiology and immunology 12/2011; 70(4):178-85.
Source: PubMed

ABSTRACT Last consensus in celiac disease in 2008 conducted under the aegis of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition jointly with North American Society of Pediatric Gastroenterology, Hepatology and Nutrition reveals the following: "celiac disease is a chronic immune-mediated enteropathy characterized by sensitization to gluten. That can affect any organ or system, with a wide range of clinical manifestations of variable severity". Thus, in recent years, clinical picture of celiac disease has changed the old paradigm--bowel disease with villous atrophy and malnutrition, being replaced with the new paradigm--multi-organ autoimmune disease, affecting many organs and systems throughout but with more less specific symptoms, which undiagnosed leads to delayed diagnosis, at a late-onset disease and long-term major complications as the risk of cancer. According to this consensus "the serological diagnosis of celiac disease is based on high sensitivity and specificity tests", but in line with changing clinical features of celiac disease, its diagnosis has undergone significant changes in recent years. These changes in the diagnosis of celiac disease, we have decided to analyze them.

Download full-text


Available from: Gabriel Samasca, Dec 23, 2013
114 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-actin antibodies are found in 52-85% of patients with autoimmune hepatitis or chronic active hepatitis and in 22% of patients with primary biliary cirrhosis. In patients with celiac disease, anti-actin antibodies correlate with the degree of villous atrophy. Studies on their involvement in celiac disease and dermatitis herpetiformis in Romania have not been done. The purpose of this study was to evaluate of the quality of IgG anti-F-actin antibodies (IgG-AAA) tests compared with IgA tissue transglutaminase antibodies (IgA-TgA) having IgA endomysial antibody (IgA-EmA) as gold standard in celiac disease and dermatitis herpetiformis and to see if there is any relationship between them. The study included 70 pediatric patients with celiac disease under gluten-free diets and 10 adult patients with dermatitis herpetiformis, during 2010. The IgG-AAA antibodies levels were determined by ELISA. Assessing the qualities of IgG-AAA compared to IgA-TgA, we obtained the following values sensitivity (Se) 27.8%, specificity (Sp) 79.4%, respectively Se 88.9%, Sp 79.4% in celiac disease and Se 33.3%, Sp 100%, respectively Se 100%, Sp 100% in dermatitis herpetiformis. Also, there was a prevalence of 24.3% and 30% of IgG-AAA in the two groups of patients, but no statistically significant associations were found. Therefore, we concluded that IgG-AAA can not replace IgA-TgA in children patients with celiac disease under gluten-free diets and in adult patients with dermatitis herpetiformis. AAA-IgG serum activity in both diseases exist, but without a relationship of association with them.
    Roumanian archives of microbiology and immunology 01/2010; 69(4):177-182.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Celiac disease (CD) is an immune-mediated disorder resulting in nutrient malabsorption now thought to have a prevalence of 1:100 in the Iranian population. Symptoms of CD are included diarrhea, abdominal pain, steatorrhea, bloating, cramps, flatulence, weight loss, weakness and short stature. In addition to presenting symptoms, patients are also at increased risk of metabolic bone disease, lymphoma (enteropathy-associated with T-cell) and other malignancies in different parts of the body such as gastric, esophageal, bladder, breast and brain. There appears to be a strong genetic component to this disease. In this short review we provided the historical, clinical and genetic aspects of this disease and highlight numerous findings from recent molecular immunology studies
  • [Show abstract] [Hide abstract]
    ABSTRACT: no abstract
    International Reviews Of Immunology 01/2014; 33(1):3-8. DOI:10.3109/08830185.2013.797414 · 4.10 Impact Factor